# Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients

Source: https://onco.cc/trials/nct07290088/  
OnCo record `nct07290088` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of PRL3-ZUMAB in advanced solid tumours, run by Intra-IMMUSG Pte Ltd, now recruiting.

## Summary

Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients is a phase 2/3 interventional study registered as NCT07290088 by Intra-IMMUSG Pte Ltd, with 52 participants planned, started 2023-01-09 and due to reach its primary completion in 2026-12. Interventions recorded: PRL3-ZUMAB.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07290088
- Phase: 2/3
- Setting: An Open Label, Multicenter, Safety and Efficacy Phase II/III Study of PRL3-Zumab in Solid Tumor Patients
- Sponsor: Intra-IMMUSG Pte Ltd
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT07290088: https://clinicaltrials.gov/study/NCT07290088

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Intra-IMMUSG](https://onco.cc/companies/intra-immusg/)

---
JSON: https://onco.cc/api/v1/entities/nct07290088.json